Bayer’s Nubeqa Files for FDA Approval in mHSPC
German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...
Company
MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion
The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK)...
Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China
China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration...
China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors
China’s National Medical Products Administration has issued marketing approval for Merck, Sharp & Dohme’s (MSD;...
Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance
US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second...
Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements
The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company...
Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...
Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment
Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...
Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib
US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa...
Jiangsu Hengrui Receives NMPA Approval for HRS-6208 Solid Tumor Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within...
InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China
China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the...
Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc.,...
Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing
China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...
United Imaging Installs AI-Powered uMR OMEGA at XRANM’s Breast Health Center
Shanghai-based United Imaging Healthcare Co., Ltd. has announced the installation of an ultra-wide-bore AI-empowered uMR...
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced the submission of a New Drug Application...
Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between...
Innovent Biologics’ IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment
The Center for Drug Evaluation (CDE) website has indicated that China-based Innovent Biologics, Inc. (HKG:...
CDE Includes Double-Crane’s Hydroxocobalamine and Sanofi Genzyme’s Fitusiran in Rare Disease Care Plan
China’s Center for Drug Evaluation (CDE) has announced the inclusion of China Resources Double-Crane Pharmaceutical...
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco,...